Tenderwize
Retour à la recherche

Non-exclusive rebate agreement for Golimumab

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Dec 31, 2026 · 125 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Golimumab (ATC-Code nach WHO: L04AB06)

46/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

46 / 100

Complexité

58 / 100

Facteurs de risque

The notice refers to key documents ('Anschreiben', 'Erläuterungen der Vertragsbedingungen', 'Einreichungsfristen') but...

The notice states that participation documents must be submitted via the DTVP communication function and not via the bi...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Dec 2026
  • Conclusion of non-exclusive rebate agreements for pharmaceutical products containing Golimumab (ATC L04AB06).
  • Open-House participation model: all interested pharmaceutical companies may join if they meet and accept the participation conditions.
Afficher le résumé complet

This is an Open-House framework-style supply arrangement for non-exclusive pharmaceutical rebate agreements for Golimumab (ATC L04AB06) with AOK PLUS. The notice states that any interested pharmaceutical company meeting the stated conditions may join during the participation period, with no individual negotiations and no exclusivity. The contract period runs until 31.12.2026 at the latest. Submission is electronic via DTVP communication, but not via the bidder tool; the first participation deadline was updated to 03.12.2025. Procurement documents are referenced but their extracted text is not provided, so key document-based details remain unverified.

Risques

The notice refers to key documents ('Anschreiben', 'Erläuterungen der Vertragsbedingungen', 'Einreichungsfristen') but...

The notice states that participation documents must be submitted via the DTVP communication function and not via the bi...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicines.

Eligibility

  • The bidder must submit the completed 'Eigenerklärung zum Nichtvorliegen von Ausschlussgründen' to evidence absence of mandatory/optional exclusion grounds under §§ 123, 124 GWB.

Administrative

  • The bidder must submit the 'Eigenerklärung Russlandsanktionen' confirming no Russia-related link within the meaning of Article 5k of Regulation (EU) 833/2014 as amended.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive rebate agreement for Golimumab

Single lot covering the conclusion of non-exclusive pharmaceutical rebate agreements under § 130a(8) SGB V for medicines containing the active substance Golimumab. The arrangement is described as an Open-House model, with no exclusivity and no individual negotiations. Performance/place of performance is stated as Dresden, Germany, but this is the notice geography and not necessarily the delivery model details.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Dec 2025 - Dec 2026

Catégorie

Pharmaceutical products

Date limite

Deadline Dec 31, 2026

Détails de la procédure

Date de publication
20 Oct 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
692978-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30